Loading
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Regular session
$21.37
−$0.41 · -1.88%
Regular session · ET · Market data may be delayed.
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
52-week range
Current $21.37
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
56
Fair Value
Sentiment
53
Mixed
Risk
75
High Risk
Momentum
49
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
52-week range
Current $21.37
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 8.5M USD | 198K USD | 821K USD | 323K USD | 2K USD |
| Cost of goods sold | 255K USD | — | — | — | — |
| Gross profit | 8.25M USD | 198K USD | 821K USD | 323K USD | 2K USD |
| Research and development | 5.53M USD | 24.57M USD | 34.19M USD | 35.46M USD | 35.57M USD |
| Selling, general, and administrative | 12.44M USD | 17.77M USD | 20.64M USD | 9.95M USD | 15.29M USD |
| Operating expenses | 17.72M USD | 42.33M USD | 54.83M USD | 45.4M USD | 50.86M USD |
| Interest income | 152K USD | 480K USD | 753K USD | 431K USD | 467K USD |
| Interest expense | 65K USD | 179K USD | 150K USD | 93K USD | 83K USD |
| Depreciation and amortization | 255K USD | 361K USD | 669K USD | 775K USD | 681K USD |
| Operating income | −9.47M USD | −42.14M USD | −54.01M USD | −45.08M USD | −50.86M USD |
| Net income | −10.94M USD | −53.86M USD | −172.6M USD | −240.81M USD | −94.8M USD |
Company facts updated Oct 9, 2026.
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 25, 2024 | 1:100 | — | — |
Effective Nov 25, 2024
1:100
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
